FINWIRES · TerminalLIVE
FINWIRES

Citigroup Adjusts Akamai Technologies Price Target to $160 From $110, Maintains Neutral Rating

By

Akamai Technologies (AKAM) has an average rating of overweight and mean price target of $157.50, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $152.59, Change: $-3.08, Percent Change: -1.98%

Related Articles

Australia

Diana Shipping Unit Extends Time Charter Contract With Oldendorff Carriers for Polymnia Vessel

Diana Shipping (DSX) said Friday that a subsidiary has extended the time charter contract with Oldendorff Carriers for Post-Panamax dry bulk vessel m/v Polymnia.The shipping company said the gross charter rate is $20,000 per day, minus a 5% commission paid to third parties, under the new charter period beginning June 1 through March 1, 2027, at the earliest and April 30, 2027, at the latest.Diana Shipping said it expects the extension to generate about $5.4 million of gross revenue for the minimum scheduled period of the time charter.Shares of Diana Shipping were down 1.5% in early trading Friday.Price: $2.72, Change: $-0.04, Percent Change: -1.52%

$DSX
Australia

Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test

Veracyte (VCYT) said Friday its TrueMRD Monitoring Test received Medicare coverage for patients with muscle-invasive bladder cancer.The diagnostic tool is approved for tracking disease recurrence following treatment, and it detected disease return median of 131 days earlier than standard imaging during clinical studies, the company said.The product will be commercially available for healthcare providers to order beginning June 1, Veracyte said.Shares of the company were down 1.1% in Friday trading.Price: $38.27, Change: $-0.63, Percent Change: -1.62%

$VCYT
Australia

Sana Biotechnology Raises $69 Million Through ATM Equity Offering

Sana Biotechnology (SANA) sold 21.6 million shares through its at-the-market equity program, raising $69 million in net proceeds, the company said Friday.The proceeds, combined with a previously disclosed $25 million investment from the Mayo Clinic, bring the company's total capital raised since the end of Q1 to $94 million, extending its cash runway into mid-2027, the company added.Shares of Sana Biotechnology were down more than 5% in recent Friday trading.Price: $2.99, Change: $-0.16, Percent Change: -4.94%

$SANA